Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Fesco increased transportation between China and Vladivostok

1/26/24 FESH

MMK's Turkish plant more than halves steel production in 2023

1/26/24 MAGN

First shipment from Arctic LNG 2 is scheduled for February

1/26/24 NVTK

Monopoly excluded Cyprus Glazifer from the chain of ownership of Globaltruck

1/25/24 GTRK

Rosneft plans to expand its presence in the Indian market

1/25/24 ROSN

Two helium units at Amursky GPP reached their design capacity

1/25/24 GAZP

SPX Exchange shareholders agreed to liquidate the Board of Directors

1/25/24 SPBE

Amur GPP will be connected to Sakhalin in 2029

1/25/24 GAZP

Henderson is ready to pay a dividend

1/25/24 HNFG

Henderson has summarized its performance in 2023

1/25/24 HNFG